TIRHOL : A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy,Treatment | Blood / Myeloma / LymphomaHodgkin's Disease (Hodgkin's Lymphoma),Lymphoma

Trial Overview Read MoreRead more

This phase II trial is trying to understand how effective a new targeted therapy is in Hodgkin's Lymphoma patients whose cancer has gotten worse or not responded to previous treatment.
 

This trial is treating patients with Hodgkin's Lymphoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

Commercial Sponsor

BeiGene Australia Pty Ltd

Other Non-Commercial Sponsor

Lymphoma Study Association

Summary

Patients with relapsed or refractory Classical Hodgkin Lymphoma (cHL) who have failed to achieve a response or progressed after receiving either an autologous hematopoietic stem cell transplantation (HSCT) or at least 2 prior systemic chemotherapy regimens and are not candidates for autologous or allogeneic HSCT, will receive 200 mg intravenously (IV) every 3 weeks (Q3W)

Recruiting Hospitals Read MoreRead more

Border Medical Oncology
Albury
Ms Nyree Sarakis
Nsarkis@bordermedonc.com.au
02 6064 1493

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next